Lin Biaoyang, Ma Yingying, Wu ShengJun
Zhejiang California International Nanosystems Institute (ZCNI) Proprium Research Center, Zhejiang University, Hangzhou, China.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
OMICS. 2022 Aug;26(8):415-421. doi: 10.1089/omi.2022.0079. Epub 2022 Aug 4.
Chronic liver disease (CLD) is a significant planetary health burden. CLD includes a broad range of liver pathologies from different causes, for example, hepatitis B virus infection, fatty liver disease, hepatocellular carcinoma, and nonalcoholic fatty liver disease or the metabolic associated fatty liver disease. Biomarker and diagnostic discovery, and new molecular targets for precision treatments are timely and sorely needed in CLD. In this context, multi-omics data integration is increasingly being facilitated by artificial intelligence (AI) and attendant digital transformation of systems science. While the digital transformation of multi-omics integrative analyses is still in its infancy, there are noteworthy prospects, hope, and challenges for diagnostic and therapeutic innovation in CLD. This expert review aims at the emerging knowledge frontiers as well as gaps in multi-omics data integration at bulk tissue levels, and those including single cell-level data, gut microbiome data, and finally, those incorporating tissue-specific information. We refer to AI and related digital transformation of the CLD research and development field whenever possible. This review of the emerging frontiers at the intersection of systems science and digital transformation informs future roadmaps to bridge digital technology discovery and clinical omics applications to benefit planetary health and patients with CLD.
慢性肝病(CLD)是一项重大的全球健康负担。CLD包括由不同病因引起的广泛肝脏病理状况,例如,乙型肝炎病毒感染、脂肪性肝病、肝细胞癌、非酒精性脂肪性肝病或代谢相关脂肪性肝病。在CLD中,迫切需要及时发现生物标志物和诊断方法,并找到精准治疗的新分子靶点。在这种背景下,人工智能(AI)以及随之而来的系统科学数字转型正越来越多地推动多组学数据整合。虽然多组学整合分析的数字转型仍处于起步阶段,但在CLD的诊断和治疗创新方面有值得关注的前景、希望和挑战。本专家综述旨在探讨大量组织水平上多组学数据整合的新兴知识前沿以及差距,包括单细胞水平数据、肠道微生物组数据,以及最后纳入组织特异性信息的数据。我们尽可能提及CLD研发领域的人工智能及相关数字转型。本综述对系统科学与数字转型交叉领域的新兴前沿进行了探讨,为连接数字技术发现与临床组学应用以造福全球健康和CLD患者提供了未来路线图。